DexCom Price To Sales Ratio from 2010 to 2024

DXCM Stock  USD 138.70  0.78  0.56%   
DexCom Price To Sales Ratio yearly trend continues to be very stable with very little volatility. Price To Sales Ratio is likely to grow to 23.85 this year. Price To Sales Ratio is a valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
14.57645557
Current Value
23.85
Quarterly Volatility
28.77577496
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many exotic indicators such as Short Term Coverage Ratios of 37.25, Price Earnings Ratio of 102 or Price To Sales Ratio of 23.85. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
  
This module can also supplement DexCom's financial leverage analysis and stock options assessment as well as various DexCom Technical models . Check out the analysis of DexCom Correlation against competitors.

Latest DexCom's Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of DexCom Inc over the last few years. Price to Sales Ratio is figured by comparing DexCom Inc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on DexCom sales, a figure that is much harder to manipulate than other DexCom Inc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period. DexCom's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 14.85 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

DexCom Price To Sales Ratio Regression Statistics

Arithmetic Mean21.58
Geometric Mean15.50
Coefficient Of Variation133.35
Mean Deviation14.06
Median15.73
Standard Deviation28.78
Sample Variance828.05
Range117
R-Value(0.33)
Mean Square Error793.13
R-Squared0.11
Significance0.23
Slope(2.14)
Total Sum of Squares11,593

DexCom Price To Sales Ratio History

2024 23.85
2023 14.58
2022 16.12
2021 22.34
2020 18.11
2019 13.5
2018 10.24

About DexCom Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include DexCom income statement, its balance sheet, and the statement of cash flows. DexCom investors use historical funamental indicators, such as DexCom's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although DexCom investors may use each financial statement separately, they are all related. The changes in DexCom's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DexCom's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on DexCom Financial Statements. Understanding these patterns can help to make the right decision on long term investment in DexCom. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Price To Sales Ratio 14.58  23.85 

Pair Trading with DexCom

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.

Moving together with DexCom Stock

  0.66COO Cooper Companies Financial Report 6th of June 2024 PairCorr

Moving against DexCom Stock

  0.65MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.62MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.52MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.49LNSR LENSAR IncPairCorr
  0.48TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out the analysis of DexCom Correlation against competitors.
Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.81
Earnings Share
1.29
Revenue Per Share
9.384
Quarterly Revenue Growth
0.269
Return On Assets
0.0641
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.